# Study of IL4 in Acute and Chronic ITP in Pediatric Patients

#### Chesis

Submitted for partial fulfillment of the master degree in Pediatrics

By

#### **Mayada Abd Elghany Ibrahim Sheleby**

M.B.B.Ch., Ain Shams University, 2008

Under Supervision of

#### **Prof. Wafaa Ezzat Ibrahim**

Professor of Pediatrics Faculty of Medicine – Ain Shams University

# Dr. Marwa Mohamed Reda Abdel Maged

Lecturer of Pediatrics
Faculty of Medicine – Ain Shams University

#### **Dr. Doaa Mohamed Abd Elaziz**

Lecturer of Clinical Pathology Faculty of Medicine – Ain Shams University

> Faculty of Medicine Ain Shams University

> > 2016



سورة البقرة الآية: ٣٢



# Acknowledgments

First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.

I wish to express my deepest gratitude and thanks to **Prof. Wafaa Ezzat Ibrahim,** Professor of Pediatrics, Faculty of Medicine – Ain Shams University, for her constructive criticism, unlimited help and giving me the privilege to work under her supervision.

My most sincere gratitude is also extended to **Dr. Marwa Mohamed Reda Abdel Maged,** Lecturer of Pediatrics,
Faculty of Medicine – Ain Shams University, for her enthusiastic help, continuous supervision, guidance and support throughout this work.

Words fail to express my appreciation to **Dr. Doaa Mohamed Abd Elaziz,** Lecturer of Clinical Pathology, Faculty of Medicine – Ain Shams University, for the time and efforts she has devoted to accomplish this work.

I can't forget to thank all **patients** and their **parents** of this study for their participation, help and cooperation during the whole procedures of the current study.

Last but not least, thanks all members of my Family, especially my **Parents** and my **Husband** for pushing me forward in every step in the journey of my life.

Candidate

Mayada Abd Elghany Ibrahim Sheleby

# **List of Contents**

Subject	PageNo.
List of Abbreviations	i
List of Tables	iii
List of Figures	v
Abstract	vi
Protocol	•••••
Aim of the Study	1
Review of Literature	
Immune Thrombocytopenia (ITP)	2
Interleukin-4	31
The Role of Cytokines in the Pathogenesis of I'	ГР 43
Subjects and Methods	50
Results	60
Discussion	76
Summary	82
Recommendations	
References	86
Appendix	
Arabic Summary	

#### **List of Abbreviations**

Abbr. Full-term

**ACTH** : Adrenocorticotropic hormone

**AD** : Atopic dermatitis

**ADO** : Adenosine

**Ag** : Antigen

**APC** : Antigen presenting cells

**ASH** : American society of heamatology

**CGRP** : Calcitonin gene related peptide

**cITP** : Chronic ITP

**CR** : Complete response

**CRH** : Corticotropin releasing hormone

**DAT** : Direct antiglobulin test

**DC** : Dendritic cell

**ELISA** : Enzyme–linked immunosorbent assays

**EMBP** : Eosinophilic major basic protein

**HPAA** : Hypothalamic pituitary adrenal axis

**IFN** : Interferon

IL : Interleukin

**IQR** : Interquartile range

**ITP** : Immune thrombocytopenic purpura

**IVIg** : Intravenous immunoglobulin

**IWG** : International Working Group

#### List of Abbreviations (Cont.)

Abbr. Full-term

**NE** : Norepinephrine

**NK** : Natural killer cells

**PaIgG**: Platelet associated IgG

**PBQ** : Pediatric bleeding questionnaire

**RBCs** : Red blood cells

**ROC** : Receiver operating characteristic

**SD** : Standard deviation

**SNS** : Sympathetic nervous system

**SP** : Substance P

Tc : T-cytotoxic

TCR : T cell's receptor

**TGF** : Transforming growth factor

**Th** : T-helper

**TNF** : Tumor necrosis factor

**TPO**: Thrombopoietin

**WBCs** : White blood cells

# **List of Tables**

Cable No	v. Title Page No
<b>Table (1):</b>	Classification of the severity of bleeding 16
<b>Table (2):</b>	Frequent examples of differential diagnosis of ITP and potential alternative causes of thrombocytopenia identified by patient history
<b>Table (3):</b>	First-line/initial treatment in children with ITP.
<b>Table (4):</b>	The scoring key for the Pediatric Bleeding Questionnaire
<b>Table (5):</b>	Number and percentage of the groups 60
<b>Table (6):</b>	Statistical comparison between groups regarding demographic data
<b>Table (7):</b>	Statistical comparison between groups regarding bleeding score
<b>Table (8):</b>	CBC parameters in acute and chronic ITP patients
<b>Table (9):</b>	Comparison between acute and chronic ITP patients regarding anemia, lymphopenia and neutropenia
<b>Table (10):</b>	Comparison between acute and chronic ITP patients regarding treatment received
<b>Table (11):</b>	Comparison between groups regarding level of IL4
<b>Table (12):</b>	Comparison between level of IL4 in the different treatment groups of acute patients71

# List of Tables (Cont.)

Table No	v. Eitle		Pag	je T	lo.
<b>Table (13):</b>	Comparison between level of different treatment groups of patients	of	chroi	nic	. 72
<b>Table (14):</b>	Correlation between level of I items in chronic patients				. 75

# **List of Figures**

Figure No.	Title Page V	lo.
Figure (1):	Pathogenic mechanisms in ITP	8
Figure (2): S	Schematic of shifts in the T-cell balance in ITP	12
Figure (3):	Summary of the complex mechanism of antiplatelet activityin patients with ITP	12
Figure (4):	Mechanisms of action of therapies for immune thrombocytopenic purpura	26
Figure (5):	IL-4 receptor complexes	36
Figure (6):	A simplified scheme of the bidirectional communication between the brain in the immune system	45
Figure (7):	Schematic of shifts in the T-cell balance in ITP	47
Figure (8):	Standard curve for human IL-4 concentration	56
Figure (9):	Example of IL-4 concentration in an acute patient	57
<b>Figure (10):</b>	Example of IL-4 concentration in a chronic patient	58
Figure (11):	Number and percentage of the groups	60
<b>Figure (12):</b>	Comparison between groups regarding sex	63
<b>Figure (13):</b>	Percentage of males and females in acute and chronic ITP groups.	63

# List of Figures (Cont.)

Figure No.	Title Page No	ν.
<b>Figure (14):</b>	Comparison between groups regarding age 6	4
<b>Figure (15):</b>	Comparison between groups regarding bleeding score	5
<b>Figure (16):</b>	Comparison between acute and chronic ITP groups regarding CBC parameters 6	7
<b>Figure (17):</b>	Comparison between acute and chronic ITP patients regarding anemia, lymphopenia and neutropenia	8
<b>Figure (18):</b>	Comparison between groups regarding treatment received	9
<b>Figure (19):</b>	Comparison between groups regarding level of IL4	0
<b>Figure (20):</b>	Comparison between level of IL4 in acute patients who received treatment and those who didn't receive	1
<b>Figure (21):</b>	Comparison between level of IL4 in chronic patients who received treatment and those who didn't receive	2
<b>Figure (22):</b>	Negative correlation between Level of IL-4 and age	4
<b>Figure (23):</b>	Negative correlation between Level of IL-4 and weight	4
<b>Figure (24):</b>	Positive correlation between level of IL4 and lymphocytic count in chronic patients 7	5

#### **ABSTRACT**

**Background:** Immune thrombocytopenia (ITP) is an autoimmune disease where platelets are destroyed prematurely. In the majority of children the disease resolves, but in some it becomes chronic. IL-4 is also termed B cell stimulatory factor 1 and is involved in B-cell activation and antibody production but also in T-cell activation. IL-4 is also known for its role in Th2 response **Aim of** the Work: This study was designed to compare IL4, bleeding score and lymphocytic count between acute and chronic ITP patient. **Subjects and methods:** The serum level of IL4 was assessed by ELISA in 20 newly diagnosed and 15 chronic ITP pediatric patients; we also compared bleeding score and lymphocytic count between both groups. Results: In this study IL4 differ significantly between newly diagnosed and chronic ITP patients with higher levels among newly diagnosed patients. However, there was no difference between both groups regarding bleeding score or lymphocytic count. Conclusion: Our data indicate that cytokine disturbances especially IL4 might be involved in the pathogenesis of newly diagnosed ITP.

**Key words:** Immune thrombocytopenia, Interleukin-4, bleeding score

#### Introduction

Immune thrombocytopenic purpura (ITP) is a heterogeneous clinical disorder characterized by immune-mediated platelet destruction. ITP is usually a benign, self-limiting disease in children (*Provan et al.*, 2010).

However, approximately 20% of childhood newly diagnosed ITP progress to a chronic form defined according to standardized criteria (*Rodeghiero et al.*, 2009).

Primary ITP was previously split into acute and chronic ITP depending on the outcome, however, the condition is today divided into 3 phases depending on the duration of thrombocytopenia after the initial diagnosis, that is newly diagnosed up to 3 months persistent ITP between 3 and 12 months, and chronic ITP beyond 12 months (*Rodeghiero et al. 2009*).

The clinical differences between newly diagnosed and chronic ITP suggest the existence of different pathophysiological mechanisms in the two forms (*Stasi et al.*, 2008).

Many researchers have investigated the role of genetic factors, humoural and cellular immunity, and inadequate platelet production in the development of this condition, but failed to identify specific characteristics of children with ITP who will probably develop the chronic form of the disorder,

mainly because of the study design and differences in patients' immunomodulating therapy (*Nugent et al.*, 2009).

Clinical findings indicate that the development of chronic ITP in children is associated with older age, less mucosal bleedings, and an insidious onset. Furthermore, chronic ITP is less likely to have had a viral illness before onset and has higher platelet count at presentation than in children with a spontaneously resolving ITP (*Glanz et al. 2008*).

At presentation there are no clinical useful biomarkers that can separate a spontaneously resolving disease from the chronic variant (*Jernas et al.*, 2013).

Nevertheless, *Semple et al.* (1996) found increased serum levels of interleukin 2 (IL-2), IL-10, and interferon-g in chronic ITP compared with acute ITP. *Del Vecchio et al.* (2012) also found increased serum levels of IL-10 in chronic versus acute ITP.

Recently *Jernas et al.* (2013) found increased levels of interleukin (IL) 16 and TNF – related weak inducer of apoptosis and lower levels of IL4 in newly diagnosed Compared with chronic ITP.

IL-4 is also termed B cell stimulatory factor 1 and is, as the name implies, involved in B-cell activation and antibody production but also in T-cell activation. IL-4 is also known for its role in Th2 response (*Yakura et al.*, 1988).

### **Aim of the Study**

The aim of this study is to compare bleeding score and lymphocytic index between acute and chronic ITP patients, we will also measure level of IL4 in both groups to assess if there is a pathophysiologic difference between both disease processes. This may help to find tools to predict disease progression.